15 years of heart-failure trials: what have we learned? (Q46626161)

23 December 2017

review article

1 reference

title

15 years of heart-failure trials: what have we learned? (English)

1 reference

23 December 2017

author name string

B M Massie

series ordinal

1

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 August 1998

1 reference

23 December 2017

published in

The Lancet

1 reference

23 December 2017

volume

352 Suppl 1

1 reference

23 December 2017

page(s)

SI29-33

1 reference

23 December 2017

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

Effects of captopril on survival in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

The effect of digoxin on mortality and morbidity in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

Classification of positive inotropic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2990016-2

7 January 2021

10.1016/S0140-6736(98)90016-2

Identifiers

DOI

1 reference

23 December 2017

PubMed ID

9736477

1 reference

23 December 2017